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As we approach the beginning of the 21st century, can 
we tell what the future holds in store for the specialty 
we are all coming to know as endovascular surgery? 
Without a doubt, it will be affected ramatically by 
factors totally independent from clinical results of the 
various procedures. Of course, satisfactory procedural 
outcomes will be demanded, and in certain ana- 
tomicopathological situations results comparable to 
classical vascular operations will be mandatory. But, 
setting aside outcomes and comparisons for the 
moment, it is important to distinguish and examine 
the "external" forces that will impact on the de- 
velopment of this burgeoning specialty. 
At least four major "extramural" pressures can be 
identified and ranked in order of importance. First, 
and by far the most influential factor, will be the 
patient. If we extrapolate from the developmental 
pattern of less invasive procedures in other specialties, 
we can expect that growing patient awareness ofendo- 
luminal vascular procedures will create a demand for 
the wire and balloon over the scalpel and suture. 
Orthopaedic surgeons now work through scopes to 
correct joint and tendon pathologies; our gastro- 
intestinal colleagues have extended the purview of the 
laparoscope far beyind its original use for chole- 
cystectomy. Indeed, every specialty is progressively 
advancing to the less invasive arena. Patients are 
demanding it - and receiving it! 
The reason patients have evolved this influence in 
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the decision to use a particular device or procedure 
relates to today's vastly expanded communication f 
scientific information to the public. Every major tele- 
vision network provides regular segments on medical 
science featuring the latest developments in both diag- 
nosis and therapy. Frequently, these programmes 
showcase a physician or hospital/university spokes- 
person extolling the virtues of some technique or 
procedure. Testimonials by patients who have be- 
nefited are frequently coupled with this scientific in- 
formation. 
Perhaps the most prominent example of this es- 
calation in medical communication is represented by 
the New England Journal of Medicine. Currently, the 
news media are briefed weekly on articles of particular 
medical interest o the lay public, usually a day or 
two before the journal is released to its subscribers. We 
have all heard the commentator n CNN announcing, 
"This week's issue of the New England Journal of Medi- 
cine describes a new approach.., a new pil l.., a new 
device..." for treating some disease or other. When 
these news releases tout a discovery in our specialty 
of vascular surgery - be it a technique, device, or drug 
- rest assured, our patients will be calling to ask 
for more information, and when the endovascular 
alternative tothe classical approach becomes available, 
there can be little doubt which one the majority of 
patients will prefer. Patients are more intimately in- 
volved than ever before in the selection of procedures 
to correct heir arterial problems, and this influence 
will only increase in the 21st century. 
The second major force that will impact on the 
development of endovascular surgery is economics. 
Health care is in a state of rapid and unsettled change 
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in most countries around the world. Unfortunately, 
these changes are not all occurring for laudable sci- 
entific reasons or even the betterment of patient care, 
for that matter. Rather, the underlying primary mo- 
tivation is to reduce the cost of health-care delivery. 
In the U.S.A. we are besieged by governmental 
pressures to cut costs, well known in the U.S.A. as 
"balancing the budget". Cardiovascular medicine and 
surgery have been at the top of the "hit" list because 
these specialities represent such a large proportion 
of US health-care xpenditures. The proposed 1998 
reductions for the professional component of several 
cardiovascular p ocedures could reach as high as 41%, 
but at a minimum we can anticipate receiving one- 
third less for our services. 
Hospitals will not be immune to the strong arm of 
the budget controller. Collectively, government and 
private health-care insurers and managed care or- 
ganisations will force a reduction in dollars expended 
for vascular care at the hospital level. Shorter hos- 
pitalisations, ame-day procedures, and the use of out- 
of-hospital extenders will be mandated. 
It is inconceivable that these pressures exist only in 
the U.S.A. Indeed, they are already being brought o 
bear worldwide. Endovascular surgery, as it matures, 
has the potential to offer some solutions to this eco- 
nomic crunch. Granted, in its early stages the tech- 
nology can be, and usually is, exorbitantly expensive. 
The manufacturers are anxious to recoup the costs of 
designing and developing a product, the financial 
investment to attain regulatory approval, and the re- 
sources expended to create a sales force for dis- 
tribution. Oftentimes, millions of dollars are spent on 
a single product, and when only one company has 
regulatory permission to sell that particular item, the 
lack of competition maintains the price. 
The hospital charge for conventional bifurcated Da- 
cron or PTFE grafts is between $250 and $600. Their 
endoluminal contemporaries begin at $5000 minimum 
and may well be over $10 000 in some complex cases 
when additional extensions, sleeves, and stents are 
applied. Under some existing reimbursement plans, 
the cost of the endoluminal prosthesis may exceed the 
total allowable amount for the entire procedure. 
On the other hand, as more competitive products 
become available and the endovascular techniques are 
perfected, cost savings can be anticipated. High initial 
device costs will decrease with competition. Hospital 
stay will decline from the average week or so for 
classical resection to periods as short as 24 h. Parallel 
reductions in morbidity and mortality will occur, and 
the patient will experience less disability with the 
opportunity to return to normal activities more rapidly. 
All of these factors will make endovascular surgery 
an appealing alternative to the higher cost classical 
procedures. In the 21st century the economic providers 
of these services will be as enthusiastic about these 
innovations as the patients who will receive them. 
There is a third major factor that will affect our 
endovascular work in the future, and it goes hand in 
glove with the excessive initial costs of new endo- 
vascular devices. In the short term, there is no question 
that high price tags on just-marketed products have a 
negative impact on the progress of our new specialty, 
but there is a mitigating factor. 
On the southern tip of Manhattan Island is an area 
called Wall Street, where there currently exists a some- 
what long-lasting love affair with technology com- 
panies. This romance is especially intense for medically 
related technology, particularly in our high-volume 
specialty. Money is available, and barring a dramatic 
economic downturn, there is more to come for de- 
velopments in the field of endovascular surgery. 
Industry is currently stoking the fire of transluminal 
therapies, supported almost unabatedly by medical 
speculators. Millions of dollars are being thrown into 
research on new products, and companies will be 
committed to promoting these products. They are 
prepared to launch a full-scale communication blitz. 
The corporate world understands the vulnerability of 
the patient-to-be. 
Simultaneously, the major corporate players have 
recognised the fact that educating the user, including 
vascular surgeons, is a key component in the ultimate 
sale of these products. We are now witnessing major 
educational programmes being developed on behalf 
of these corporations to bring al l  potential in- 
terventionists up to acceptable skill levels. The end 
result is greater emphasis on endovascular surgical 
procedures being created by the same people who 
market he device. Sound corporate strategy! 
The assurance of a longer, disease-free life has been 
a major goal for our people in this century. Prenatal 
care, preventive medicine, and earlier disease detection 
with appropriate intervention have all given rise to the 
fourth major influence on the future of endovascular 
surgery: the ever-growing aged population in de- 
veloped countries, the very people in whom endo- 
luminal therapy can be most beneficial. 
With increasing age comes more prevalence of 
cardiovascular disease, both occlusive and an- 
eurysmal. We previously considered 65 years of age 
to be time for retirement and not long after for ascent 
to the heavens beyond. Today, it is not unusual to 
encounter octogenarians whose mental and physical 
status are excellent except for some specific vascular 
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problem - a tight carotid lesion, an iliac stenosis, or a 
6 cm aneurysm of the abdominal aorta. There will be 
a great emphasis on treating these eldery patients with 
less invasive methods. As indicated earlier, technology 
will become less expensive, as will the cost of de- 
livering it. While there may be arguments at various 
levels regarding the appropriateness of using the "ex- 
pensive" technology for treatment in the elderly popu- 
lation, I would predict that the pressures applied by 
the patients and their advocates will prevail. The result 
will be a greater emphasis on delivery of endoluminal 
therapy. 
Regardless of these extramural pressures and many 
others that will be identified, none of this future will 
unfold if the science of endovascular technology fails 
to reach its expectations. The likelihood of that hap- 
pening in the 21st century is, in my opinion, distinctly 
remote. Endovascular stent technology has already 
secured a permanent role in treating aortic and iliac 
artery occlusive disease. Classical renal artery bypass 
for the treatment of renovascular hypertension has 
already succumbed to highly satisfactory results of 
stenting ostial renal lesions. Even the indication for 
renal stenting has expanded to encompass the pre- 
servation of renal function. The classical surgical ap- 
proach to aortic arch vessel occlusive disease with its 
associated morbidity and mortality is no match for 
endovascular techniques, particularly as newer stent 
designs become available. Endoluminal graft tech- 
nology, alluded to earlier, is still in its infancy, but the 
results using second-generation devices already clearly 
indicate that traumatic, occlusive, and aneurysmal 
disease will be treated endoluminally in most arterial 
locations. 
Two exceptions must be considered, however. Endo- 
luminal procedures below the inguinal igament have 
not enjoyed the same degree of success as in the larger 
limb and trunk vessels. Atherectomy, stenting, and 
even endoluminal grafting still require refinement, 
the potential for satisfactory outcomes is there. This 
is definitely a challenging area for endovascular in- 
terventions in the future. 
The question of stenting the carotid bifurcation will 
undoubtedly be the most vehemently contested issue 
leading into the next century. My personal prediction 
is that there will be specific subgroups of patients in 
whom the procedure will be justified, but unbridled 
use will definitely lead to disastrous results. 
On the horizon, we can anticipate further develop- 
ments in covered stent echnology to positively impact 
restenosis and the embolic process. Laser therapy, 
proven of little benefit in either recanalisation or re- 
stenosis inhibition, is currently being applied to stent 
restenosis. Beta and gamma radiation studies using 
both superficial femoral and coronary artery stents are 
looking quite promising in the fight to reduce intimal 
hyperplasia. Heparin-coated stents are just the be- 
ginning of a whole host of pharmacological pos- 
sibilities to treat restenosis and, even more importantly, 
to affect he atherosclerotic disease process itself. Gene 
therapy, just in its infancy, will certainly play a role 
in angiogenesis and the manipulation of metabolic 
processes in the next few years. 
Where Will Endovascular Surgery Be in the 21st 
Century? 
Patients will demand less invasive procedures, third- 
party payers will endorse the lower cost techniques, 
and the products will become less expensive in the 
hands of skilled practitioners. Hence, endovascular 
surgery will move progressively into a leadership 
position in the treatment of vascular disease despite 
those who may continue to discredit its value and 
champion the classical position. 
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